A comparative study of efficacy and safety of montelukast levocetrizine and montelukast fexofenadine in patients with allergic rhinitis was written by Achankunju, Soumya Annu;Rajaram, S.;Mukesh, K.;Kaladharan, Anakha. And the article was included in World Journal of Pharmaceutical Research in 2022.Recommanded Product: 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid The following contents are mentioned in the article:
To study and compare the efficacy of montelukastlevocetrizine and montelukast-fexofenadine by comparing the safety profiles of two combination therapy in patients with allergic rhinitis. This was a prospective comparative parallel group study. A total of 60 patients of either gender aged between 18-65 with mild persistent or moderate to severe intermittent allergic rhinitis were enrolled for the study. Total Nasal Symptom Score, ECG and basic blood investigations (Absolute esinophils count) was done before the study. After detailed history and clin. examination the patients were divided into two groups. One group receiving a fixed drug combination of tab. Montelukast 10mg + Levocetrizine 5 mg once daily dose and the other group receiving Montelukast 10mg + Fexofenadine 120mg once daily at bed time for a period of 30 days. Patients were asked to come after 15 days (first visit) and again after 15 days (final visit). Demog., clin. and laboratory reports of enrolled patients were recorded and analyzed. There was a significant reduction in nasal symptoms (TNSS) and diagnostic parameter (AEC). In both the groups, the TNSS at visit 0 and 2 was compared, there was a high degree of significance (p<0.001). When AEC at visit 0 and 2 was compared, there was a significant reduction p<0.001. In this study, both the group has shown significant reduction in nasal symptoms and AEC. The tolerability profile was also analyzed and both the combinations were found to be equally tolerable. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Recommanded Product: 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid).
2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. The piperidine ring can be found not only in more than half of the currently known structures of alkaloids, but also in many natural or synthetic compounds with interesting biological activities. Several piperidine alkaloids isolated from natural herbs, were found to exhibit antiproliferation and antimetastatic effects on various types of cancers both in vitro and in vivo for example Piperine, Evodiamine, Matrine, Berberine and Tetrandine.Recommanded Product: 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem